Terms: = Pancreatic cancer AND Neurokinin
19 results:
1. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study.
Hishida-Sadaka S; Iihara H; Ohata K; Matsuoka S; Watanabe D; Iwashita T; Uemura S; Shimizu M; Suzuki A
Support Care Cancer; 2023 Oct; 31(12):657. PubMed ID: 37884842
[TBL] [Abstract] [Full Text] [Related]
2. A Substance P (SP)/neurokinin-1 Receptor Axis Promotes Perineural Invasion of pancreatic cancer and Is Affected by lncRNA LOC389641.
Ji T; Ma K; Wu H; Cao T
J Immunol Res; 2022; 2022():5582811. PubMed ID: 35600049
[TBL] [Abstract] [Full Text] [Related]
3. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
[TBL] [Abstract] [Full Text] [Related]
4. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H; Izawa N; Kawaguchi T; Miyaji T; Shimomura K; Kazunori H; Iihara H; Ohno Y; Inada Y; Arioka H; Morita H; Hida N; Sugawara M; Katada C; Nawata S; Ishida H; Tsuboya A; Tsuda T; Yamaguchi T; Nakajima TE
BMJ Open; 2020 Dec; 10(12):e041737. PubMed ID: 33334838
[TBL] [Abstract] [Full Text] [Related]
5. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.
Tran CG; Sherman SK; Scott AT; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2021 Feb; 28(2):732-741. PubMed ID: 32656719
[TBL] [Abstract] [Full Text] [Related]
6. Protective effect of diallyl disulfide against cerulein-induced acute pancreatitis and associated lung injury in mice.
Mathan Kumar M; Tamizhselvi R
Int Immunopharmacol; 2020 Mar; 80():106136. PubMed ID: 31991372
[TBL] [Abstract] [Full Text] [Related]
7. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells.
Huang C; Li Y; Guo Y; Zhang Z; Lian G; Chen Y; Li J; Su Y; Li J; Yang K; Chen S; Su H; Huang K; Zeng L
Theranostics; 2018; 8(11):3074-3086. PubMed ID: 29896303
[TBL] [Abstract] [Full Text] [Related]
8. PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk.
Sinha S; Fu YY; Grimont A; Ketcham M; Lafaro K; Saglimbeni JA; Askan G; Bailey JM; Melchor JP; Zhong Y; Joo MG; Grbovic-Huezo O; Yang IH; Basturk O; Baker L; Park Y; Kurtz RC; Tuveson D; Leach SD; Pasricha PJ
Cancer Res; 2017 Apr; 77(8):1868-1879. PubMed ID: 28386018
[TBL] [Abstract] [Full Text] [Related]
9. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract] [Full Text] [Related]
10. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract] [Full Text] [Related]
11. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract] [Full Text] [Related]
12. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract] [Full Text] [Related]
13. Tachykinins and their receptors in human malignancies.
Palma C
Curr Drug Targets; 2006 Aug; 7(8):1043-52. PubMed ID: 16918332
[TBL] [Abstract] [Full Text] [Related]
14. Immunolocalization of full-length NK1 tachykinin receptors in human tumors.
Schulz S; Stumm R; Röcken C; Mawrin C; Schulz S
J Histochem Cytochem; 2006 Sep; 54(9):1015-20. PubMed ID: 16651388
[TBL] [Abstract] [Full Text] [Related]
15. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut.
Ardill JE; Erikkson B
Endocr Relat Cancer; 2003 Dec; 10(4):459-62. PubMed ID: 14713258
[TBL] [Abstract] [Full Text] [Related]
16. neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer.
Friess H; Zhu Z; Liard V; Shi X; Shrikhande SV; Wang L; Lieb K; Korc M; Palma C; Zimmermann A; Reubi JC; Büchler MW
Lab Invest; 2003 May; 83(5):731-42. PubMed ID: 12746482
[TBL] [Abstract] [Full Text] [Related]
17. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid.
Hanna FW; Ardill JE; Johnston CF; Cunningham RT; Curry WJ; Russell CF; Buchanan KD
J Endocrinol; 1997 Feb; 152(2):275-81. PubMed ID: 9071985
[TBL] [Abstract] [Full Text] [Related]
18. Substance-P receptors in human primary neoplasms: tumoral and vascular localization.
Hennig IM; Laissue JA; Horisberger U; Reubi JC
Int J Cancer; 1995 Jun; 61(6):786-92. PubMed ID: 7790112
[TBL] [Abstract] [Full Text] [Related]
19. [Gastrointestinal hormone profile in medullary thyroid carcinoma].
Wirth HP; Eberle C; Meyenberger C; Bertschinger P; Häcki WH; Ammann R; Heitz PU
Schweiz Med Wochenschr; 1994 May; 124(21):906-11. PubMed ID: 8016606
[TBL] [Abstract] [Full Text] [Related]
